ArticleCell & bioscience2026
The TSPY gene and the loss of Y chromosome predisposition to cancers.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Mosaic loss of Y chromosome is a common genetic phenomenon in elderly men. It predisposes affected individuals to cancers, suggesting that genes on this male-specific chromosome contribute to the well-being of men. Currently, the putative gene(s) responsible for such cancer predisposition when lost is/are currently unknown. A recent study identified the testis-specific protein Y-encoded (TSPY) gene possesses significant immunogenicity, capable of eliciting significant immune responses against and eliminating positive tumor cells in a mouse model of liver cancer. TSPY is a male-specific cancer-testis antigen expressed in a wide variety of cancers but not normal somatic cells. It is an ampliconic gene constituting a majority (~ 42%) of all protein-coding genes on the human Y chromosome. TSPY is hypothesized to be a guardian gene for man, protecting man from cancer development. Its high copy-number of conserved functional units ensures that it is intrinsically activated in early/progenitor cancer cells, thereby eliciting robust immune responses, eliminating early tumor progenitor cells and preempting oncogenic progression and tumor development. Loss of TSPY gene cluster together with the loss of the entire Y chromosome in oncogenic progenitor/early tumor cells provide a favorable environment fostering oncogenic development, thereby predisposing elderly men to cancers.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.